CIK 0001703647 · Non-accelerated filer<br>Smaller reporting company
Korro Bio, Inc.
Sign in to watch- Ticker
- KRRO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472324450
- Phone
- 617-468-1999
- Business address
- 60 FIRST STREET, 2ND FLOOR, SUITE 250, CAMBRIDGE, MA, 02141
- Former names
- Frequency Therapeutics, Inc.
- Open-market buys, last 90 days
- $884,752
- in 1 filing
- Open-market sales, last 90 days
- $2,161,962
- in 6 filings, $2.2M under 10b5-1 plans
Net −$1,277,210. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-11 | Agarwal Vineet Chief Financial Officer | Option exercise 10b5-1 | +800 | $11.68 | $9K | 800 |
| 2024-11-11 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −800 | $70.00 | $56K | 0 |
| 2024-11-11 | Agarwal Vineet Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −800 | 30,807 | ||
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Option exercise 10b5-1 | +9,263 | $11.68 | $108K | 9,263 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Option exercise 10b5-1 | +953 | $14.98 | $14K | 10,216 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −2,023 | $71.51 | $145K | 8,193 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −164 | $73.71 | $12K | 8,029 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −115 | $74.56 | $9K | 7,914 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −56 | $76.00 | $4K | 7,858 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −23 | $77.00 | $2K | 7,835 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −260 | $77.55 | $20K | 7,575 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −457 | $78.59 | $36K | 7,118 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −1,815 | $79.79 | $145K | 5,303 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −4,961 | $80.50 | $399K | 342 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −317 | $81.48 | $26K | 25 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Sale 10b5-1 | −25 | $82.89 | $2K | 0 |
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,263 | 31,607 | ||
| 2024-10-17 | Agarwal Vineet Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −953 | 45,594 | ||
| 2024-09-03 | Cerio Jeffrey General Counsel | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-08-26 | Knobil Katharine Director | Grant or award · Stock Option (Right to Buy) | +9,041 | 9,041 |
Page 6 of 10 · 188 trades